Estrella Immunopharma opens new trial site for cancer therapy

EMERYVILLE, Calif. - Estrella Immunopharma Inc. (NASDAQ: ESLA), a biopharmaceutical company, has announced the opening of a new clinical trial site for its STARLIGHT-1 Phase I/II study, which is evaluating EB103, an experimental T-cell therapy for B-cell non-Hodgkin’s lymphoma (NHL). The Baylor Research Institute in Dallas, Texas, has begun enrolling patients for this trial.

The STARLIGHT-1 trial is an open-label, dose-escalation study aimed at assessing the safety of EB103 and determining the appropriate dose for Phase II trials in adults with relapsed or refractory B-cell NHL. The trial includes a dose escalation phase followed by an expansion phase, with further details available on the clinicaltrials.gov website under the identifier NCT06343311. With the company’s next earnings report due on June 23, investors following this development can access comprehensive financial analysis and 7 additional key insights through InvestingPro.

EB103, also known as Estrella’s CD19-Redirected ARTEMIS® T-Cell Therapy, is designed to target CD19, a protein found on the surface of almost all B-cell leukemias and lymphomas. This therapy, which uses ARTEMIS® technology licensed from Eureka Therapeutics, Estrella’s parent company, differs from traditional CAR-T cell therapies in that it uses a mechanism that more closely resembles that of an endogenous T-cell receptor, which could potentially offer a more regulated and safer treatment option.

Estrella Immunopharma focuses on developing T-cell therapies targeting CD19 and CD22 to treat various cancers and autoimmune diseases. The company is also developing EB104, which targets both CD19 and CD22.

The press release also contains forward-looking statements regarding the potential benefits and therapeutic advantages of EB103 and ARTEMIS® T-cell therapy, anticipated progress of the STARLIGHT-1 trial, and future development plans for EB103. These statements reflect the company’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. InvestingPro data indicates the company’s overall financial health score is FAIR, with analysts not anticipating profitability this year.

This news is based on a press release statement from Estrella Immunopharma, Inc.

In other recent news, Estrella Immunopharma, Inc. has announced a private investment in public equity (PIPE) financing deal expected to generate approximately $3.35 million. The agreement involves issuing over 2.3 million shares at $1.50 each, which is above the last reported sale price. The funds are designated for advancing Phase I of the STARLIGHT-1 clinical trial, focusing on EB103, Estrella’s CD19-Redirected ARTEMIS® T-cell therapy for adults with relapsed or refractory B-cell non-Hodgkin’s lymphoma. The closing of this financing deal is subject to customary conditions, and the company plans to file a registration statement with the SEC for the resale of the securities issued. The securities offered have not been registered under the Securities Act of 1933. Estrella’s CEO, Cheng Liu, noted that investor confidence reflects belief in the potential of the company’s ARTEMIS® T-cell therapy platform. EB103 is designed to target CD19, a protein found on most B-cell leukemias and lymphomas, while another product, EB104, targets both CD19 and CD22. These developments are part of Estrella’s strategy to harness the human immune system to combat cancer and other diseases.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.